Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation

Transplantation

Volumn 77, Issue 10, 2004, Pages 1500-1506

  Gruessner, Rainer W G ^a   Levay Young, Brett K ^a   Nakhleh, Raouf E ^b   Shearer, Jeffry D ^a   Dunning, Michele ^a   Nelson, Curtis M ^a   Gruessner, Angelika C ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ARGININE; CYTOKINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE SYNTHASE; PREDNISONE; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD TRANSFUSION; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; LIVER BIOPSY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PORTAL VEIN; PRIORITY JOURNAL; SWINE;

ANIMALS; BLOOD TRANSFUSION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INTESTINES; MALE; MYCOPHENOLIC ACID; NITRIC OXIDE; PORTAL SYSTEM; STEROIDS; SURVIVAL ANALYSIS; SWINE; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION CHIMERA;

EID: 2542589312     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000128298.12937.B2     Document Type: Article

References (33)

1. Grant DR. Intestinal Transplant Registry. http: //www.intestinaltransplant.org. Accessed 19 February 2003.
2. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg 2001; 234: 404.
3. Pirenne J, Gruessner AC, Benedetti E, et al. Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. Surgery 1997; 121: 79.
4. Gruessner RW, Uckun FM, Pirenne J, et al. Recipient preconditioning and donor-specific bone marrow infusion in a pig model of total bowel transplantation. Transplantation 1997; 63: 12.
5. Gruessner RW, Nakhleh RE, Harmon JV, et al. Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. Transplantation 1998; 66: 164.
6. Langrehr JM, Machens C, Zill E, et al. Inhibition of nitric oxide synthesis reduces bacterial translocation during graft-versus-host disease after small bowel transplantation. Transplant Proc 1999; 31: 574.
7. Mattsson P, Zeevi A, Cai J, et al. Effect of aminoguanidine and cyclosporine on lung allograft rejection. Ann Thorac Surg 1996; 62: 207.
8. Kimura H, Katsuramaki T, Isobe M, et al. Role of inducible nitric oxide synthase in pig liver transplantation. J Surg Res 2003; 111: 28.
9. Worrall NK, Boasquevisque CH, Botney MD, et al. Inhibition of inducible nitric oxide synthase ameliorates functional and histological changes of acute lung allograft rejection. Transplantation 1997; 63: 1095.
10. Worrall NK, Misko TP, Sullivan PM, et al. Inhibition of inducible nitric oxide synthase attenuates established acute cardiac allograft rejection. Ann Thorac Surg 1996; 62: 378.
11. Misko TP, Moore WM, Kasten TP, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119.
12. Nakhleh, RE, Gruessner AC, Pirenne J, et al. Colon vs. small bowel rejection after total bowel transplantation in a pig model. Transpl Int 1996; 9(Suppl 1): S269.
13. Bordonaro M, Saccomanno CF, and Nordstrom JL. An improved T1/A ribonuclease protection assay. Biotechniques 1994; 16: 428.
14. McGraw RA, Jacobson RJ, and Akamatsu M. A male-specific repeated DNA sequence in the domestic pig. Nucleic Acids Res 1988; 16: 10389.
15. Wu T, Levay-Young B, Heuss N, et al. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation 2002; 74: 22.
16. Tashiro H, Fukuda Y, Kimura A, et al. Assessment of microchimerism in rat liver transplantation by polymerase chain reaction. Hepatology 1996; 23: 828.
17. Alard P, Matriano JA, Socarras S, et al. Detection of donor-derived cells by polymerase chain reaction in neonatally tolerant mice. Microchimerism fails to predict tolerance. Transplantation 1995; 60: 1125.
18. Cantor HM and Dumont AE. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature 1967; 215: 744.
19. Wolf YG, Dunaway DJ, Harmel RP. Small bowel transplantation following portal venous injection of donor strain spleen cells. Transplant Proc 1990; 22: 2493.
20. Gorczynski RM, Chan Z, Chung S, et al. Prolongation of rat small bowel or renal allograft survival by pretransplant transfusion and/or by varying the route of allograft venous drainage. Transplantation 1994; 58: 816.
21. Fecteau AH, Tchervenkov JI, Guttman FM, et al. Small bowel transplantation. Transplantation 1994; 58: 399.
22. Fujiwara H, Qian JH, Satoh S, et al. Studies on the induction of tolerance to alloantigens. II. The generation of serum factors able to transfer alloantigen-specific tolerance for delayed-type hypersensitivity by portal venous inoculation with allogeneic cells. J Immunol 1986; 136: 2763.
23. Quian JH, Hashimoto T, Fujiwara H, et al. Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity responses to alloantigens by portal venous inoculation with allogeneic cell. J Immunol 1985; 134: 3656.
24. Nakafusa Y, Terasaka R, Matsuo K, et al. Advantages of donor-specific blood transfusion in the rat via the portal vein for renal transplantation. Am J Kidney Dis 1993; 21: 433.
25. Sato K, Yabuki K, Haba T, et al. Role of Kupffer cells in the induction of tolerance after liver transplantation. J Surg Res 1996; 63: 433.
26. Callery MP, Mangino MJ, Flye MW. Arginine-specific suppression of mixed lymphocyte culture reactivity by Kupffer cells.: a basis of portal venous tolerance. Transplantation 1991; 51: 1076.
27. Kamei T, Callery MP, Flye MW. Kupffer cells blockade prevents induction of portal venous tolerance in rat cardiac allograft transplantation. J Surg Res 1990; 48: 393.
28. Levay-Young B, Gruessner SE, Shearer JD, et al. Intestinal graft versus native liver cytokine expression in a rat model of intestinal transplantation with and without donor-specific cell augmentation. J Surg Res 2003; (in press).
29. Nakao A, Kobayashi E, Shen SD, et al. Impact of tacrolimus and bone marrow augmentation on intestinal allograft survival and agraft cytokine expression in rats. J Med 32; 2001: 207.
30. Koshiba T, Van Damme B, Ji P, et al. Addition of steroids blocks the tolerogenic potential of donor-specific transfusion. Transplant Proc 2001; 33: 375.
31. Harmon JV, Gruessner AC, Nakhleh R, et al. Experimental short-term immunosuppression after bowel transplantation and donor-specific bone marrow infusion in a large animal model. Arch Surg 2001; 136: 817.
32. Morin N, Lamoureux E, Lipman M, et al. Donor-specific portal transfusion augments microchimerism in a porcine model of small bowel transplantation. Transplant Proc 2000; 32: 1290.
33. Pirenne J, Koshiba T, Geboes K, et al. Complete freedom from rejection after intestinal transplantation using a new tolerogenic protocol combined with low immunosuppression. Transplantation 2002; 73: 966.